Pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Erasmus University Medical Center, department of Surgery
Eligibility
Inclusion criteria
Inclusion criteria: • Age = 18 years. • Diagnosed with (borderline) resectable, locally advanced or metastatic PDAC. • Treatment with FOLFIRINOX chemotherapy, including neoadjuvant therapy in the investigational group ór treatment with gemcitabine (with nab-paclitaxel) in the control group. • Written informed consent (either for PANCAKE in case of locally advanced PDAC and metastasized PDAC or for the PREOPANC-3 trial in case of (borderline) resectable PDAC).
Exclusion criteria
Exclusion criteria: • Combined treatment with other chemotherapeutics then FOLFIRINOX. • Previous treatment with FOLFIRINOX chemotherapy. • Pregnancy. • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in circulating tumor DNA, microRNAs, SNPs, and cytokines between patients with disease control and patients with progressive disease during FOLFIRINOX treatment and sensitivity and specificity of these biomarkers. | — |
Contacts
Public ContactFleur van der Sijde
Erasmus University Medical Center
Outcome results
None listed